Home › Funds › Pivotal bioVenture Partners Investment Advisor LLC › ZBIO

Pivotal bioVenture Partners Investment Advisor LLC position in ZBIO

ZENAS BIOPHARMA INC · Health Care

Pivotal bioVenture Partners Investment Advisor LLC reported holding 233,176 shares of ZBIO (ZENAS BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$6.3M, representing 2.56% of its reported portfolio and ranking #10 among its reported holdings. Pivotal bioVenture Partners Investment Advisor LLC has disclosed ZBIO holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

Latest position (Q3 2026)233.18K sh
Reported value held$6.29M
Portfolio Weight2.56%
First reportedQ3 2024
Last changeReduce
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Pivotal bioVenture Partners Investment Advisor LLC's ZBIO position evolved

Pivotal bioVenture Partners Investment Advisor LLC first disclosed a stake in ZBIO in Q3 2024 at 650,695 shares (US$11.0M). The position peaked in Q4 2025 at 591,991 shares, worth US$21.5M. Across 9 filings, Pivotal bioVenture Partners Investment Advisor LLC increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 3 time(s). The most recent filing (Q3 2026) shows 233,176 shares valued at US$6.3M — a reduction of -257,590 shares quarter over quarter.. Notable position changes include a 52% trim in Q3 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 650.70K $11.01M New
Q4 2024 736.64K $6.03M Add
Q1 2025 736.64K $5.82M Hold
Q2 2025 779.04K $7.55M Add
Q3 2025 779.04K $17.29M Hold
Q4 2025 591.99K $21.50M Reduce
Q1 2026 591.99K $11.57M Hold
Q2 2026 490.77K $12.46M Reduce
Q3 2026 233.18K $6.29M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ZBIO and 13F data

ZBIO (ZENAS BIOPHARMA INC) is a Health Care company. 63 other funds we track also report a position in ZBIO — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$127.9M), NEA Management Company, LLC (US$102.1M), Enavate Sciences GP, LLC (US$99.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ZBIO

All ZBIO fund holders →

FAQ

How long has Pivotal bioVenture Partners Investment Advisor LLC held ZBIO?

Pivotal bioVenture Partners Investment Advisor LLC has disclosed ZBIO holdings in 9 of the last 9 reported quarters, going back to Q3 2024.

What is Pivotal bioVenture Partners Investment Advisor LLC's current position in ZBIO?

As of Q3 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 233.18K shares of ZBIO (ZENAS BIOPHARMA INC), valued at $6.29M, representing 2.56% of its reported portfolio and ranking #10.

Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling ZBIO?

In the latest 13F filing (Q3 2026), Pivotal bioVenture Partners Investment Advisor LLC reduced its position in ZBIO. The position peaked in Q4 2025 at 591.99K shares.

Which other funds hold ZBIO?

Other major institutional holders of ZBIO include SR ONE CAPITAL MANAGEMENT, LP, NEA Management Company, LLC, Enavate Sciences GP, LLC, among 63 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.